AstraZeneca completes Cellectis equity investment
7 May 2024 AstraZeneca completes equity investment agreement with Cellectis AstraZeneca today announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company. The equity investment and a research collaboration agreement, announced in November 2023 will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design up to 10 novel cell and gene therapy products for areas of